MedTrace Logo

Evaluation of the RD-X19 Treatment Device in Individuals With Mild to Moderate COVID-19

NCT04966013 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 216

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

This is a randomized, sham controlled, dose finding study of the EmitBio RD-X19 device in individuals with symptomatic COVID-19 in the outpatient setting.

Conditions

  • COVID19

Interventions

DEVICE

RD-X19

Investigational device that uses safe electromagnetic energy to target the oropharynx.

DEVICE

Sham

Investigational device that uses safe electromagnetic energy to target the oropharynx but at energy levels with a lower inactivation potential against SARS-CoV-2 in vitro..

Sponsors & Collaborators

  • EmitBio Inc.

    lead INDUSTRY

Principal Investigators

  • Study Director · EmitBio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-17
Primary Completion
2022-01-05
Completion
2022-02-23
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04966013 on ClinicalTrials.gov